There are currently 66 active clinical trials seeking participants for Renal Cell Carcinoma research studies. The states with the highest number of trials for Renal Cell Carcinoma participants are California, Texas, New York and Florida.
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
NCT04792463
Recruiting
This research will have a significant impact on the overall management of those cancer patients and their family members who are at risk for hereditary cancer due to germline inactivation of BAP1. Our study will ultimately facilitate the development of novel screening, prevention and treatment strategies for these individuals with the syndrome. Because the vast majority of UM develop in pre-existing nevi, characterization of individuals at high risk for development of UM will allow closer screen... Read More
Gender:
ALL
Ages:
All
Trial Updated:
01/17/2025
Locations: The Ohio State University Wexner Medical Center, Columbus, Ohio
Conditions: Uveal Melanoma, Cutaneous Melanoma, BAP1 Gene Mutation, Renal Cell Carcinoma, Mesothelioma, Hepatocellular Carcinoma, Cholangiocarcinoma, Meningioma Atypical
Register for Updates
TFE Renal Cell Carcinoma: A Prospective Registry and Translational Research Initiative
NCT03630536
Recruiting
There are limited data regarding the biology and treatment of TFE Renal Cell Carcinoma (TFE RCC). This project provides the infrastructure for acquisition of biological specimens, imaging, and correlative clinical data to facilitate biology studies and characterization of TFE RCC. This registry will collect clinical, demographic, and pathological data, specimens (as available) and imaging from patients with TFE RCC, prospectively. Cases are identified through: 1. Existing clinical and/or cancer... Read More
Gender:
ALL
Ages:
All
Trial Updated:
09/17/2024
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Renal Cell Carcinoma
Register for Updates
A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
NCT05789069
Recruiting
The purpose of this study is to test the safety and tolerability of HFB200603 as a single agent and in combination with tislelizumab in patients with advanced cancers. There are two parts in this study. During the escalation part, groups of participants will receive increasing doses of HFB200603 as a monotherapy or in combination with tislelizumab until a safe and tolerable dose of HFB200603 as a single agent or combination therapy is determined. During the expansion part, participants will take... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/12/2025
Locations: USC Norris Comprehensive Cancer Center, Los Angeles, California +10 locations
Conditions: Renal Cell Carcinoma, Melanoma, Non Small Cell Lung Cancer, Gastric Cancer, Colorectal Cancer
Register for Updates
Contrast-Enhanced Ultrasound Imaging for Diagnosing Recurrent Renal Cell Carcinoma (RCC) Post Ablation
NCT05641935
Recruiting
This phase II trial studies how well contrast-enhanced ultrasound (CEUS) works for diagnosing patients with renal cell cancer (RCC) that has come back (recurrent) after an ablation. Diagnostic imaging, such as CEUS, may help find and monitor long term renal cell cancer recurrence following cryo or microwave ablation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania
Conditions: Recurrent Renal Cell Carcinoma, Renal Cell Carcinoma
Register for Updates
A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma
NCT06699602
Recruiting
The researchers are doing this study to find out whether it is practical (feasible) to give cemiplimab and fianlimab before a nephrectomy and whether it causes any delays with surgery in people with kidney cancer. The researchers will also look at whether cemiplimab and fianlimab given before a nephrectomy is a safe and effective treatment approach and if there is a change in the size of the tumor following immunotherapy prior to planned surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: Memorial Sloan Kettering Basking Ridge (Limited Protocol Activites), Basking Ridge, New Jersey +6 locations
Conditions: Renal Cell Carcinoma
Register for Updates
Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.
NCT05501054
Recruiting
To learn if the combination of ciforadenant, ipilimumab, and nivolumab can help to control advanced renal cell carcinoma
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/07/2025
Locations: Duke Cancer Institute, Durham, North Carolina +2 locations
Conditions: Renal Cell Carcinoma
Register for Updates
A Study of Adjuvant V940 and Pembrolizumab in Renal Cell Carcinoma (V940-004).
NCT06307431
Recruiting
The primary objective of the study is to compare V940 plus pembrolizumab to placebo plus pembrolizumab in participants with renal cell carcinoma (RCC) with respect to disease-free survival (DFS) as assessed by the investigator. The primary hypothesis is that V940 plus pembrolizumab is superior to placebo plus pembrolizumab with respect to DFS.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/07/2025
Locations: City of Hope Comprehensive Cancer Center-Medical Oncology ( Site 0104), Duarte, California +62 locations
Conditions: Renal Cell Carcinoma
Register for Updates
A Study of VET3-TGI in Patients With Solid Tumors
NCT06444815
Recruiting
VET3-TGI is an oncolytic immunotherapy designed to treat advanced cancers. VET3-TGI has not been given to human patients yet, and the current study is designed to find a safe and effective dose of VET3-TGI when administered by direct injection into tumor(s) (called an intratumoral injection) or when given intravenously (into the vein) both alone and in combination with pembrolizumab in patients with solid tumors (STEALTH-001).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/04/2025
Locations: USC/Norris Comprehensive Cancer Center, Los Angeles, California +5 locations
Conditions: Solid Tumor, Adult, Microsatellite Stable Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Cancer, Kidney Cancer, Renal Cell Carcinoma, Melanoma Stage IV, Merkel Cell Carcinoma of Skin, Mesothelioma, Non-small Cell Lung Cancer
Register for Updates
Neoadjuvant Lenvatinib and Pembrolizumab for IVC Tumor Thrombus
NCT05319015
Recruiting
This study will be evaluating safety and efficacy of the combination of lenvatinib and pembolizumab neoaadjuvant therapy prior to surgical resection of locally advanced renal cell carcinoma with IVC tumor thrombus.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/30/2025
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Renal Cell Carcinoma
Register for Updates
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
NCT03228667
Recruiting
This Phase 2b, multicohort, open-label clinical trial (QUILT-3.055) evaluates combination immunotherapies in patients with various advanced solid tumors who have progressed following prior PD-1/PD-L1 checkpoint inhibitor therapy. The trial includes six cohorts: Cohorts 1-4: Patients who progressed after an initial response (PR or CR) to prior PD-1/PD-L1 therapy, receiving combination therapy with N-803 and a PD-1/PD-L1 checkpoint inhibitor. (Closed to enrollment) Cohort 5: Patients who progres... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/27/2025
Locations: Alaska Clinical Research Center, Anchorage, Alaska +34 locations
Conditions: Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma, Merkel Cell Carcinoma, Melanoma, Renal Cell Carcinoma, Gastric Cancer, Cervical Cancer, Hepatocellular Carcinoma, Microsatellite Instability, Mismatch Repair Deficiency, Colorectal Cancer
Register for Updates
Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)
NCT06005818
Recruiting
The goal of this Clinical Study is to understand the outcomes by informing therapy choice for adjuvant treatment in clear cell renal cell carcinoma by using molecular residual disease. The main question\[s\] it aims to answer are: * what is the progression free survival of a cohort of high risk resected RCC patients when treated based on MRD * what is the overall survival of high risk resected RCC patients when treated based on MRD Participants will forgo adjuvant therapy with pembrolizumab i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/26/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Renal Cell Carcinoma
Register for Updates
A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer
NCT06580938
Recruiting
The purpose of this study is to learn about the safety and effects of the study medicine (called PF-07921585) in people with cancer that has advanced or spread to other parts of the body. This study is seeking participants who have any of the following cancer types: * non-small cell lung cancer * colorectal cancer * bladder cancer * melanoma (a type of skin cancer) * kidney cancer * head and neck cancer Participants will receive the study medicine PF-07921585 alone or in combination with anoth... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/23/2025
Locations: Highlands Oncology Group, Fayetteville, Arkansas +7 locations
Conditions: Non Small Cell Lung Cancer, Bladder Cancer, Renal Cell Carcinoma, Melanoma, Head and Neck Cancer, Colorectal Cancer
Register for Updates